- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses ADA's Efforts to Address Effect of Diabetes on Kidney Disease
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), describes the ADA's efforts to elevate the conversation about the impact of diabetes on kidney disease.
Most people who have chronic kidney disease do not know they have it and are not getting screened, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.
Transcript
The introduction of newer therapies to prevent renal decline has brought attention to the need for improved monitoring of patients with diabetes. Can you discuss ADA’s efforts in this area?
The American Diabetes Association has been really concerned about the impact of diabetes on renal disease for some time. Diabetes is the leading cause for end-stage renal disease in the US, and so it is a major contributor to a host of morbidity and mortality associated with kidney disease. The unfortunate thing is that most people are not aware that they have chronic kidney disease and are not being screened. We are about to launch a national effort to really elevate the conversation around kidney disease. And stay tuned in the coming months, we'll be announcing some exciting work that will expand on the work we're already doing in this area, but we really think the time has come to tackle this in a big way.
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
